457 related articles for article (PubMed ID: 34486476)
1. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients.
Shao J; Zhang B; Kuai L; Li Q
Bioengineered; 2021 Dec; 12(1):6186-6200. PubMed ID: 34486476
[TBL] [Abstract][Full Text] [Related]
2. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
Jin D; Song Y; Chen Y; Zhang P
Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
Chen J; Fu Y; Hu J; He J
Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
[TBL] [Abstract][Full Text] [Related]
5. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
[TBL] [Abstract][Full Text] [Related]
6. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
8. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
Chen Y; Zhang X; Li J; Zhou M
J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
[TBL] [Abstract][Full Text] [Related]
9. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
11. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
13. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma.
Song J; Sun Y; Cao H; Liu Z; Xi L; Dong C; Yang R; Shi Y
Bioengineered; 2021 Dec; 12(1):5932-5949. PubMed ID: 34488540
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
15. An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma.
Li Y; Sun X
Front Genet; 2022; 13():768971. PubMed ID: 35368654
[No Abstract] [Full Text] [Related]
16. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
Liu J; Wu H; Gao Z; Lou M; Yuan K
Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
[TBL] [Abstract][Full Text] [Related]
17. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
18. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract][Full Text] [Related]
19. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response.
Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
